Stage
No active trials
Next date
None yet
Trials
0 active
3 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks”In the company’s words, NCT03603314 on ClinicalTrials.gov
- Tested for
- Severe Sudden Sensorineural Hearing Loss, Hearing Loss, Hearing Loss Ototoxic
- Main trialPhase 2/3
- “Primary objective of the study is to assess the efficacy of SENS-401 on hearing loss in comparison to placebo at the end of the 4-week treatment period”In the company’s words, NCT03603314 on ClinicalTrials.gov
Other drugs for Hearing Loss
- EbselenSound Pharmaceuticals, Incorporated · Phase 3
- Isosorbide oral solutionLunan Better Pharmaceutical Co., LTD. · Phase 2/3
- LY888891Eli Lilly · Phase 3
- KP-100ITKringle Pharma, Inc. · Phase 3
- N-acetylcysteine amideNacuity Pharmaceuticals, Inc. · Phase 3
- SonlicromanolKhondrion BV · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Completed | 4 Nov 2021 | Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss | |
| Phase 2Completed | 18 Dec 2023 | Evaluation of the Presence of SENS-401 in the Perilymph | |
| Phase 2Completed | 16 Apr 2025 | SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026